An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder

NCT00360126 | Completed Phase 4 Results

• 1 other identifier: SCA104753
• Study Type: interventional
• Target: 11
• Locations: 1 country
• Sites: 3

Brief Summary

The precursor study (SCA101469) was an open-label, prospective multicentre study in adult subjects diagnosed with bipolar disorder consisting of 36 weeks treatment with lamotrigine. The current study is to provide 12 months post study access to open-label lamotrigine for participants of the SCA101469 study.

Conditions

Bipolar Disorder

Keywords

Lamictal; lamotrigine; Open-Label Extension Study; Bipolar Disorder

Outcome Measures

Primary Outcomes (1)

• Number of Participants With Serious Adverse Events (SAEs)

  An adverse event (AE) is defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event is therefore any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect. Only SAEs were recorded and reported in this extension study.

  Up to 54 weeks

Interventions

lamotrigine DRUG

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• completed 32 weeks of open label treatment in study SCA101469 and, in the investigators opinion, has responded to lamotrigine therapy
• male or female subject
• A female is eligible to enter and participate in this study if she is of:
• non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal or sterilised) or,
• child-bearing potential, has a negative urine pregnancy test at screening, and agrees to one of the following contraceptive methods:
• Complete abstinence from intercourse from 2 weeks prior to administration of the study drug, throughout the study, and for a time interval after completion of premature discontinuation from the study to account for elimination of the investigational drug (a minimum of 5 half-lives or longer if the pharmacodynamic profile of the investigational drug warrants a longer time period); or,
• Sterilisation of male partner; or,
• Implants of levonorgestrel; or,
• Injectable progestogen; or,
• Oral contraceptive (combined or progestogen only); or,
• Any intrauterine device (IUD) with published data showing that the lowest expected failure rate is less than 1% per year (not all IUDs meet this criterion); or,
• Any other methods with published data showing that the lowest expected failure rate for that method is less than 1% per year; or,
• Barrier method only if used in combination with any of the above acceptable methods.
• willing and able to give written informed consent to participate in the study.

You may not qualify if:

• subject experienced a 'mood episode' during participation in study SCA101469, or since completing participation in study SCA101469.
• participation in a clinical drug trial other than SCA101469 within the past 30 days or previous participation in this clinical study
• known hypersensitivity to lamotrigine
• in the investigator's judgement, the subject poses a current serious suicidal or homicidal risk, or has made a suicide attempt within the past 6 months.
• combination of carbamazepine and valproate
• concurrent lamotrigine therapy, other than that commenced in study SCA101469
• current or history of substance abuse
• diagnosis of epilepsy
• diagnosis or history of an obsessive-compulsive disorder, social phobia, or eating disorder
• significant cardiac, renal, cerebrovascular, or hepatic condition; no significant abnormalities in the laboratory tests or ECG recording performed during study SCA101469.
• unable to understand or implement instructions
• unresolved drug related adverse event or serious adverse event occurring in study SCA101469

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (3)

GSK Investigational Site

Greenwich, New South Wales, 2065, Australia

Location

GSK Investigational Site

Everton Park, Queensland, 4053, Australia

Location

GSK Investigational Site

New Farm, Queensland, 4005, Australia

Location

MeSH Terms

Conditions

Bipolar Disorder

Interventions

Lamotrigine

Condition Hierarchy (Ancestors)

Bipolar and Related Disorders; Mood Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Triazines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Results Point of Contact

• Title: GSK Response Center
• Organization: GlaxoSmithKline

866-435-7343

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 2, 2006
• First Posted: August 3, 2006
• Study Start: October 1, 2005
• Primary Completion: February 1, 2007
• Study Completion: February 1, 2007
• Last Updated: March 30, 2017
• Results First Posted: March 30, 2017

Record last verified: 2017-02

Locations

AU (3)